Anti-Leishmania Tropica Activity of Candida Abicans Proteinase

Abstract

Cutaneous leishmaniasis is the most common form of leishmaniasis. It is a skin infection caused by a single-celled parasite that is transmitted by sand fly bites. Although the cutaneous form of the disease is often self-limiting, it does result in significant scarring and can spread to more invasive, mucocutaneous disease. Leishmaniasis is endemic in 88 countries on five continents. The pentavalent antimonials meglumine antimonate (85 mg Sb/mL) for intramuscular administration and sodium stibogluconate (100 mg Sb/mL) for intravenous and intramuscular administration have been used for decades for the treatment of New World cutaneous leishmaniasis, and are the gold standard for other new investigational drugs. Cutaneous leishmaniasis has been treated in patients of all ages with a wide range of physical methods, including cauterization, surgical excision, cryotherapy and the application of local heat. The antibacterial activity of proteinase was determined against different types of bacteria isolated from patients and healthy individuals. The most sensitive bacteria were Lactobacillus spp. While Pseudomonas aeruginosa is the most resistant. Candidal proteinase, also have an anti-leishmania donovani activity ( on the promastigote stage)[15] . Thus this study was conducted to evaluate the effect of proteinase enzyme on promastigote stage of L. tropica, in vitro and the possibility to be used in the future as an anti-leishmanial drug.